Pictet Asset Management (UK)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pictet Asset Management (UK)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$420K	Sell	4,400 -600	-12%	-$62.5K	﹤0.01%	1289
2021 Q1	$569K	Buy	5,000 +300	+6%	+$40.8K	﹤0.01%	1161
2020 Q4	$651K	Hold	4,700	–	–	﹤0.01%	1097
2020 Q3	$386K	Buy	+4,700	New	+$390K	﹤0.01%	1139
2019 Q3	–	Sell	-306,325	Closed	-$19.5M	–	1036
2019 Q2	$19.5M	Sell	306,325 -270,636	-47%	-$17.2M	0.04%	393
2019 Q1	$40M	Sell	576,961 -325,142	-36%	-$18.6M	0.09%	273
2018 Q4	$39.2K	Buy	902,103 +311,764	+53%	+$17M	0.1%	259
2018 Q3	$45.1M	Sell	590,339 -50,634	-8%	-$4.12M	0.1%	256
2018 Q2	$49.3M	Sell	640,973 -438,396	-41%	-$28.3M	0.12%	231
2018 Q1	$55M	Buy	1,079,369 +64,900	+6%	+$3.27M	0.14%	213
2017 Q4	$47.1M	Buy	1,014,469 +264,062	+35%	+$12.9M	0.12%	228
2017 Q3	$40M	Buy	750,407 +161,196	+27%	+$9.55M	0.11%	234
2017 Q2	$31.7M	Buy	589,211 +173,433	+42%	+$10.4M	0.1%	265
2017 Q1	$28.2M	Buy	415,778 +28,228	+7%	+$2.15M	0.09%	277
2016 Q4	$27.2M	Buy	387,550 +49,431	+15%	+$3.51M	0.1%	257
2016 Q3	$24M	Buy	338,119 +143,592	+74%	+$9.17M	0.09%	275
2016 Q2	$14.2M	Buy	194,527 +186,927	+2,460%	+$12.1M	0.06%	357
2016 Q1	$464K	Hold	7,600	–	–	﹤0.01%	794
2015 Q4	$853K	Buy	7,600 +4,700	+162%	+$470K	﹤0.01%	791
2015 Q3	$279K	Sell	2,900 -28,700	-91%	-$3.29M	﹤0.01%	843
2015 Q2	$3.82M	Sell	31,600 -10,700	-25%	-$831K	0.02%	645
2015 Q1	$2.39M	Buy	+42,300	New	+$2.35M	0.01%	719

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pictet Asset Management (UK)'s RARE Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Ultragenyx Pharmaceutical (RARE) stake by 12% in Q2 2021, selling an estimated $62.5K and leaving 4,400 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #1289.

Pictet Asset Management (UK) first reported a position in RARE in Q1 2015 and has held it in 22 quarters since. The position peaked at $55M in Q1 2018. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Pictet Asset Management (UK) held 4,400 shares of Ultragenyx Pharmaceutical worth $420K as of Q2 2021.
Pictet Asset Management (UK) sold 600 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $62.5K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1289 holding.
Pictet Asset Management (UK) first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 22 quarters since.
Pictet Asset Management (UK)'s Ultragenyx Pharmaceutical position peaked at $55M in Q1 2018.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.